Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities

Journal of Medicinal Chemistry

Volumn 51, Issue 24, 2008, Pages 8038-8047

  Bulaj, Grzegorz ^a   Green, Brad R ^a   Lee, Hee Kyoung ^a   Robertson, Charles R ^a   White, Karen ^a   Zhang, Liuyin ^a   Sochanska, Marianna ^a   Flynn, Sean P ^a   Scholl, Erika Adkins ^a   Pruess, Timothy H ^a   Smith, Misty D ^a   White, H Steve ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GALANIN B2; GALANIN DERIVATIVE; GALANIN RECEPTOR; NAX 5055; NONESSENTIAL AMINO ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EPILEPSY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; LIMBIC CORTEX; LIPOPHILICITY; MASS SPECTROMETRY; MICELLE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; ROTAROD TEST; SEIZURE; STRUCTURE ACTIVITY RELATION;

AMINO ACID MOTIFS; ANIMALS; ANTICONVULSANTS; BLOOD-BRAIN BARRIER; BRAIN; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; EPILEPSY; GALANIN; KINETICS; LIGANDS; MICE; MODELS, CHEMICAL; MOLECULAR CONFORMATION;

EID: 58149089158     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801088x     Document Type: Article

References (84)

1. Hokfelt, T.; Broberger, C.; Xu, Z. Q.; Sergeyev, V.; Ubink, R.; Diez, M. Neuropeptides - an overview. Neuropharmacology 2000, 39, 1337-1356.
2. Baraban, S. C.; Tallent, M. K. Interneuron Diversity series: Interneuronal neuropeptides - endogenous regulators of neuronal excitability. Trends Neurosci. 2004, 27, 135-142.
3. Lerner, J. T.; Sankar, R.; Mazarati, A. M. Galanin and epilepsy. Cell. Mol. Life Sci. 2008, 65, 1864-1871.
4. Baraban, S. C. Neuropeptide Y and epilepsy: recent progress, prospects and controversies. Neuropeptides 2004, 38, 261-265.
5. Vezzani, A.; Sperk, G.; Colmers, W. F. Neuropeptide Y: emerging evidence for a functional role in seizure modulation. Trends Neurosci. 1999, 22, 25-30.
6. Vezzani, A.; Hoyer, D. Brain somatostatin: a candidate inhibitory role in seizures and epileptogenesis. Eur. J. Neurosci. 1999, 11, 3767-3776.
7. Solbrig, M. V.; Koob, G. F. Epilepsy, CNS viral injury and dynorphin. Trends Pharmacol. Sci. 2004, 25, 98-104.
8. Mazarati, A.; Lundstrom, L.; Sollenberg, U.; Shin, D.; Langel, U.; Sankar, R. Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: The effects of subtype-selective agonists and the role of G-protein-mediated signaling. J. Pharmacol. Exp. Ther. 2006, 318, 700-708.
9. Tallent, M. K.; Qiu, C. Somatostatin: An endogenous antiepileptic. Mol. Cell. Endocrinol. 2008, 286, 96-103.
10. Richichi, C.; Lin, E. J.; Stefanin, D.; Colella, D.; Ravizza, T.; Grignaschi, G.; Veglianese, P.; Sperk, G.; During, M. J.; Vezzani, A. Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 2004, 24, 3051-3059.
11. Noe, F.; Nissinen, J.; Pitkanen, A.; Gobbi, M.; Sperk, G.; During, M.; Vezzani, A. Gene therapy in epilepsy: the focus on NPY. Peptides 2007, 28, 377-383.
12. Noe, F.; Pool, A. H.; Nissinen, J.; Gobbi, M.; Bland, R.; Rizzi, M.; Balducci, C.; Ferraguti, F.; Sperk, G.; During, M. J.; Pitkanen, A.; Vezzani, A. Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain 2008, 131, 1506-1515.
13. Mazarati, A. M.; Halaszi, E.; Telegdy, G. Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats. Brain Res. 1992, 589, 164-166.
14. Kokaia, M.; Holmberg, K.; Nanobashvili, A.; Xu, Z. Q.; Kokaia, Z.; Lendahl, U.; Hilke, S.; Theodorsson, E.; Kahl, U.; Bartfai, T.; Lindvall, O.; Hokfelt, T. Suppressed kindling epileptogenesis in mice with ectopic overexpression of galanin. Proc. Natl. Acad. Sci. U.S.A 2001, 98, 14006-14011.
15. Mazarati, A. M.; Liu, H.; Soomets, U.; Sankar, R.; Shin, D.; Katsumori, H.; Langel, U.; Wasterlain, C. G. Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J. Neurosci. 1998, 18, 10070-10077.
16. Saar, K.; Mazarati, A. M.; Mahlapuu, R.; Hallnemo, G.; Soomets, U.; Kilk, K.; Hellberg, S.; Pooga, M.; Tolf, B. R.; Shi, T. S.; Hokfelt, T.; Wasterlain, C.; Bartfai, T.; Langel, U. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc. Natl. Acad. Sci. U.S.A 2002, 99, 7136-7141.
17. Haberman, R. P.; Samulski, R. J.; McCown, T. J. Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat. Med. 2003, 9, 1076-1080.
18. Lin, E. J.; Richichi, C.; Young, D.; Baer, K.; Vezzani, A.; During, M. J. Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur. J. Neurosci. 2003, 18, 2087-2092.
19. Bartfai, T.; Lu, X.; Badie-Mahdavi, H.; Barr, A. M.; Mazarati, A.; Hua, X. Y.; Yaksh, T.; Haberhauer, G.; Ceide, S. C.; Trembleau, L.; Somogyi, L.; Krock, L.; Rebek, J., Jr. Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc. Natl. Acad. Sci. U.S.A 2004, 101, 10470-10475.
20. Mazarati, A. M.; Hohmann, J. G.; Bacon, A.; Liu, H.; Sankar, R.; Steiner, R. A.; Wynick, D.; Wasterlain, C. G. Modulation of hippocampal excitability and seizures by galanin. J. Neurosci. 2000, 20, 6276-6281.
21. Schlifke, I.; Kuteeva, E.; Hokfelt, T.; Kokaia, M. Galanin expressed in the excitatory fibers attenuates synaptic strength and generalized seizures in the piriform cortex of mice. Exp. Neurol. 2006, 200, 398-406.
22. Zini, S.; Roisin, M. P.; Langel, U.; Bartfai, T.; Ben-Ari, Y. Galanin reduces release of endogenous excitatory amino acids in the rat hippocampus. Eur. J. Pharmacol. 1993, 245, 1-7.
23. Hokfelt, T.; Xu, Z. Q.; Shi, T. J.; Holmberg, K.; Zhang, X. Galanin in ascending systems. Focus on coexistence with 5-hydroxytryptamine and noradrenaline. Ann. N.Y. Acad. Sci. 1998, 863, 252-263.
24. Branchek, T. A.; Smith, K. E.; Gerald, C.; Walker, M. W. Galanin receptor subtypes. Trends Pharmacol. Sci. 2000, 21, 109-117.
25. Lundstrom, L.; Elmquist, A.; Bartfai, T.; Langel, U. Galanin and its receptors in neurological disorders. Neuromol. Med 2005, 7, 157-180.
26. Burgevin, M. C.; Loquet, I.; Quarteronet, D.; Habert-Ortoli, E. Cloning, pharmacological characterization, and anatomical distribution of a rat cDNA encoding for a galanin receptor. J. Mol. Neurosci. 1995, 6, 33-41.
27. Mazarati, A.; Lu, X.; Kilk, K.; Langel, U.; Wasterlain, C.; Bartfai, T. Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur. J. Neurosci. 2004, 19, 3235-3244.
28. Mazarati, A.; Lu, X.; Shinmei, S.; Badie-Mahdavi, H.; Bartfai, T. Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice. Neuroscience 2004, 128, 431-441.
29. Pirondi, S.; Fernandez, M.; Schmidt, R.; Hokfelt, T.; Giardino, L.; Calza, L. The galanin-R2 agonist AR-M1896 reduces glutamate toxicity in primary neural hippocampal cells. J. Neurochem. 2005, 95, 821-833.
30. Hwang, I. K.; Yoo, K. Y.; Kim, D. S.; Do, S. G.; Oh, Y. S.; Kang, T. C.; Han, B. H.; Kim, J. S.; Won, M. H. Expression and changes of galanin in neurons and microglia in the hippocampus after transient forebrain ischemia in gerbils. Brain Res. 2004, 1023, 193-199.
31. Ceide, S. C.; Trembleau, L.; Haberhauer, G.; Somogyi, L.; Lu, X.; Bartfai, T.; Rebek, J., Jr. Synthesis of galmic: a nonpeptide galanin receptor agonist. Proc. Natl. Acad. Sci. U.S.A 2004, 101, 16727-16732.
32. Lu, X.; Barr, A. M.; Kinney, J. W.; Sanna, P.; Conti, B.; Behrens, M. M.; Bartfai, T. A role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus. Proc. Natl. Acad. Sci. U.S.A 2005, 102, 874-879.
33. Badie-Mahdavi, H.; Behrens, M. M.; Rebek, J.; Bartfai, T. Effect of galnon on induction of long-term potentiation in dentate gyrus of C57BL/6 mice. Neuropeptides 2005, 39, 249-251.
34. Lu, X.; Lundstrom, L.; Langel, U.; Bartfai, T. Galanin receptor ligands. Neuropeptides 2005, 39, 143-146.
35. Poduslo, J. F.; Curran, G. L. Glycation increases the permeability of proteins across the blood-nerve and blood-brain barriers. Brain Res. Mol. Brain Res. 1994, 23, 157-162.
36. Poduslo, J. F.; Curran, G. L. Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J. Neurochem. 1996, 66, 1599-1609.
37. Witt, K. A.; Gillespie, T. J.; Huber, J. D.; Egleton, R. D.; Davis, T. P. Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability. Peptides 2001, 22, 2329-2343.
38. Tatemoto, K.; Rokaeus, A.; Jornvall, H.; McDonald, T. J.; Mutt, V. Galanin - a novel biologically active peptide from porcine intestine. FEBS Lett. 1983, 164, 124-128.
39. Langel, U.; Bartfai, T. Chemistry and molecular biology of galanin receptor ligands. Ann. N.Y. Acad. Sci. 1998, 863, 86-93.
40. Land, T.; Langel, U.; Low, M.; Berthold, M.; Unden, A.; Bartfai, T. Linear and cyclic N-terminal galanin fragments and analogs as ligands at the hypothalamic galanin receptor. Int. J. Pept. Protein Res. 1991, 38, 267-272.
41. Fisone, G.; Berthold, M.; Bedecs, K.; Unden, A.; Bartfai, T.; Bertorelli, R.; Consolo, S.; Crawley, J.; Martin, B.; Nilsson, S.; et al. N-terminal galanin-(1-16) fragment is an agonist at the hippocampal galanin receptor. Proc. Natl. Acad. Sci. U.S.A 1989, 86, 9588-9591.
42. 2 is important for stabilizing an N-terminal helix. Biochemistry 1999, 38, 15295-15304.
43. Jureus, A.; Langel, U.; Bartfai, T. L-Ala-substituted rat galanin analogs distinguish between hypothalamic and jejunal galanin receptor subtypes. J. Pept. Res. 1997, 49, 195-200.
44. Pooga, M.; Jureus, A.; Razaei, K.; Hasanvan, H.; Saar, K.; Kask, K.; Kjellen, P.; Land, T.; Halonen, J.; Maeorg, U.; Uri, A.; Solyom, S.; Bartfai, T.; Langel, U. Novel galanin receptor ligands. J. Pept. Res. 1998, 51, 65-74.
45. Rivera Baeza, C.; Kask, K.; Langel, U.; Bartfai, T.; Unden, A. Analogs of galanin (1-16) modified in positions 1-3 as ligands to rat hypothalamic galanin receptors. Acta Chem. Scand. 1994, 48, 434-438.
46. Dasgupta, P.; Singh, A.; Mukherjee, R. N-terminal acylation of somatostatin analog with long chain fatty acids enhances its stability and antiproliferative activity in human breast adenocarcinoma cells. Biol. Pharm. Bull. 2002, 25, 29-36.
47. Blanchfield, J. T.; Dutton, J. L.; Hogg, R. C.; Gallagher, O. P.; Craik, D. J.; Jones, A.; Adams, D. J.; Lewis, R. J.; Alewood, P. F.; Toth, I. Synthesis, structure elucidation, in vitro biological activity, toxicity, and Caco-2 cell permeability of lipophilic analogues of a-conotoxin MII. J. Med. Chem. 2003, 46, 1266-1272.
48. Blanchfield, J. T.; Lew, R. A.; Smith, A. I.; Toth, I. The stability of lipidic analogues of GnRH in plasma and kidney preparations: the stereoselective release of the parent peptide. Bioorg. Med. Chem. Lett. 2005, 15, 1609-1612.
49. Yuan, L.; Wang, J.; Shen, W. C. Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide. Pharm. Res. 2005, 22, 220-227.
50. Wang, J.; Wu, D.; Shen, W. C. Structure-activity relationship of reversibly lipidized peptides: studies of fatty acid-desmopressin conjugates. Pharm. Res. 2002, 19, 609-614.
51. van de Waterbeemd, H.; Lennernas, H.; Artursson, P. Drug Bioavailability: Estimation of Solubility, Permeability, Adsorption and Bioavailability; Wiley-VCH Verlag GmbH & Co: Germany, 2003.
52. Dagar, S.; Onyuksel, H.; Akhter, S.; Krishnadas, A.; Rubinstein, I. Human galanin expresses amphipathic properties that modulate its vasoreactivity in vivo. Peptides 2003, 24, 1373-1380.
53. Cai, L. F.; Gochin, M. Colloidal aggregate detection by rapid fluorescence measurement of liquid surface curvature changes in multiwell plates. J. Biomol. Screening 2007, 12, 966-971.
54. Dyson, H. J.; Rance, M.; Houghten, R. A.; Wright, P. E.; Lerner, R. A. Folding of immunogenic peptide fragments of proteins in water solution. II. The nascent helix. J. Mol. Biol. 1988, 201, 201-217.
55. Dyson, H. J.; Merutka, G.; Waltho, J. P.; Lerner, R. A.; Wright, P. E. Folding of peptide fragments comprising the complete sequence of proteins. Models for initiation of protein folding. I. Myohemerythrin. J. Mol. Biol. 1992, 226, 795-817.
56. Shin, H. C.; Merutka, G.; Waltho, J. P.; Wright, P. E.; Dyson, H. J. Peptide models of protein folding initiation sites. 2. The G-H turn region of myoglobin acts as a helix stop signal. Biochemistry 1993, 32, 6348-6355.
57. Morris, M. B.; Ralston, G. B.; Biden, T. J.; Browne, C. L.; King, G. F.; Iismaa, T. P. Structural and biochemical studies of human galanin: NMR evidence for nascent helical structures in aqueous solution. Biochemistry 1995, 34, 4538-4545.
58. Valenzano, K. J.; Miller, W.; Kravitz, J. N.; Samama, P.; Fitzpatrick, D.; Seeley, K. Development of a fluorescent ligand-binding assay using the AcroWell filter plate. J. Biomol. Screening 2000, 5, 455-461.
59. Sollenberg, U.; Bartfai, T.; Langel, U. Galnon - a low-molecular-weight ligand of the galanin receptors. Neuropeptides 2005, 39, 161-163.
60. Boules, M.; Fredrickson, P.; Richelson, E. Bioactive analogs of neurotensin: Focus on CNS effects. Peptides 2006, 27, 2523-2533.
61. Egleton, R. D.; Davis, T. P. Bioavailability and transport of peptides and peptide drugs into the brain. Peptides 1997, 18, 1431-1439.
62. Egleton, R. D.; Davis, T. P. Development of neuropeptide drugs that cross the blood-brain barrier. NeuroRx 2005, 2, 44-53.
63. Dasgupta, P.; Mukherjee, R. Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro. Br. J. Pharmacol. 2000, 129, 101-109.
64. Uchiyama, T.; Kotani, A.; Tatsumi, H.; Kishida, T.; Okamoto, A.; Okada, N.; Murakami, M.; Fujita, T.; Fujiwara, Y.; Kiso, Y.; Muranishi, S.; Yamamoto, A. Development of novel lipophilic derivatives of DADLE (leucine enkephalin analogue): intestinal permeability characateristics of DADLE derivatives in rats. Pharm. Res. 2000, 17, 1461-1467.
65. Wang, J.; Hogenkamp, D. J.; Tran, M.; Li, W. Y.; Yoshimura, R. F.; Johnstone, T. B.; Shen, W. C.; Gee, K. W. Reversible lipidization for the oral delivery of leu-enkephalin. J. Drug Targeting 2006, 14, 127-136.
66. Banks, W. A.; Kastin, A. J. Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability. Brain Res. Bull. 1985, 15, 287-292.
67. Fuchs, S. M.; Raines, R. T. Internalization of cationic peptides: the road less (or more?) traveled. Cell. Mol. Life Sci. 2006, 63, 1819-1822.
68. Drin, G.; Cottin, S.; Blanc, E.; Rees, A. R.; Temsamani, J. Studies on the internalization mechanism of cationic cell-penetrating peptides. J. Biol. Chem. 2003, 278, 31192-31201.
69. Tamai, I.; Sai, Y.; Kobayashi, H.; Kamata, M.; Wakamiya, T.; Tsuji, A. Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. J. Pharmacol. Exp. Ther. 1997, 280, 410-415.
70. Drin, G.; Rousselle, C.; Scherrmann, J. M.; Rees, A. R.; Temsamani, J. Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. AAPS PharmSci 2002, 4, E26.
71. Pajouhesh, H.; Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005, 2, 541-553.
72. Kurtzhals, P.; Havelund, S.; Jonassen, I.; Kiehr, B.; Larsen, U. D.; Ribel, U.; Markussen, J. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem. J. 1995, 312 (Pt 3), 725-731.
73. Havelund, S.; Plum, A.; Ribel, U.; Jonassen, I.; Volund, A.; Markussen, J.; Kurtzhals, P. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm. Res. 2004, 21, 1498-1504.
74. Menezo, Y.; Khatchadourian, C. Peptides bound to albumin. Life Sci 1986, 39, 1751-1753.
75. Svenson, J.; Brandsdal, B. O.; Stensen, W.; Svendsen, J. S. Albumin binding of short cationic antimicrobial micropeptides and its influence on the in vitro bactericidal effect. J. Med. Chem. 2007, 50, 3334-3349.
76. Mazarati, A. M. Galanin and galanin receptors in epilepsy. Neuropeptides 2004, 38, 331-343.
77. Nelson, A. R.; Borland, L.; Allbritton, N. L.; Sims, C. E. Myristoyl-based transport of peptides into living cells. Biochemistry 2007, 46, 14771-14781.
78. Zorko, M.; Langel, U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv. Drug Delivery Rev. 2005, 57, 529-545.
79. Pooga, M.; Hallbrink, M.; Zorko, M.; Langel, U. Cell penetration by transportan. FASEB J. 1998, 12, 67-77.
80. Pooga, M.; Soomets, U.; Hallbrink, M.; Valkna, A.; Saar, K.; Rezaei, K.; Kahl, U.; Hao, J. X.; Xu, X. J.; Wiesenfeld-Hallin, Z.; Hokfelt, T.; Bartfai, T.; Langel, U. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 1998, 16, 857-861.
81. Tossi, A.; Sandri, L.; Giangaspero, A. Amphipathic, α-helical antimicrobial peptides. Biopolymers 2000, 55, 4-30.
82. Hua, X. Y.; Hayes, C. S.; Hofer, A.; Fitzsimmons, B.; Kilk, K.; Langel, U.; Bartfai, T.; Yaksh, T. L. Galanin acts at GalR1 receptors in spinal antinociception: synergy with morphine and AP-5. J. Pharmacol. Exp. Ther. 2004, 308, 574-582.
83. Hua, X. Y.; Salgado, K. F.; Gu, G.; Fitzsimmons, B.; Kondo, I.; Bartfai, T.; Yaksh, T. L. Mechanisms of antinociception of spinal galanin: how does galanin inhibit spinal sensitization. Neuropeptides 2005, 39, 211-216.
84. Liu, H. X.; Brumovsky, P.; Schmidt, R.; Brown, W.; Payza, K.; Hodzic, L.; Pou, C.; Godbout, C.; Hokfelt, T. Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: selective actions via GalR1 and GalR2 receptors. Proc. Natl. Acad. Sci. U.S.A 2001, 98, 9960-9964.